Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab in Relapsed/Refractory Cancer of Unknown Primary (CheCUP)
NCT04131621Phase 2Unknown
- Sponsor
- Heidelberg University Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in cancer of unknown primary (CUP), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-Free Survival at 3 months. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT04131621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131621.